Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.

The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.